Issue Date: September 10, 2012
Janssen Licenses Genmab Cancer Drug
Janssen Biotech, an arm of Johnson & Johnson, will pay Genmab $55 million up front for access to the monoclonal antibody daratumumab and a backup antibody. As part of the deal, J&J will invest roughly $80 million in the Danish biotech company. Janssen will also take on development costs for daratumumab, including paying for ongoing Phase I/II clinical trials in patients with multiple myeloma. Daratumumab binds to CD38, a protein on the surface of several kinds of immune cells.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society